Skip to main content
S&P 5007,739.02+0.45%DOW51,758.79+0.80%NASDAQ27,073.40+0.50%BTC$83,801.00-0.41%ETH$2,686.54+0.54%GOLD$4,319.50+0.50%OIL$92.22-2.53%
Smart Investors Daily
EV

NASDAQ · EVMT

Invesco Electric Vehicle Metals Commodity Strategy No K-1 ETF

Financial Services · Asset Management

$17.95

Down-$0.01 (-0.03%)

Updated Sep 25, 2026, 5:03 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
7.83M
P/E ratio
—
Dividend yield
2.95%
52-week range
$15.60 – $20.50
Volume
1.29K
Avg. volume
6.1K

Price performance

EVMT price history

1M range · 20 trading sessions · Daily adjusted prices

EVMT closed at $17.95 after 20 trading sessions, up 0.81% for the selected period.

Last close
$17.95
Period change
+0.81%
Period low
$17.51
Period high
$18.19
Daily close
View OHLC price history
EVMT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 24, 2026$17.80$17.945$17.80$17.9451.29K
Sep 23, 2026$17.85$17.9381$17.84$17.93812.86K
Sep 22, 2026$18.03$18.0577$18.00$18.0577396.67
Sep 21, 2026$17.96$17.96$17.895$17.8952.61K
Sep 18, 2026$17.8886$17.8886$17.8886$17.8886271.89
Sep 17, 2026$17.76$17.76$17.76$17.76322.15
Sep 16, 2026$17.62$17.62$17.54$17.54327.98
Sep 15, 2026$17.63$17.63$17.475$17.505571.92
Sep 14, 2026$17.565$17.66$17.565$17.5989546.48
Sep 11, 2026$17.74$17.80$17.68$17.759.91K
Sep 10, 2026$17.725$17.75$17.68$17.681.06K
Sep 9, 2026$18.175$18.29$18.175$18.193.22K
Sep 8, 2026$18.00$18.12$17.92$17.97231.3K
Sep 4, 2026$17.94$17.9678$17.94$17.96782.78K
Sep 3, 2026$17.85$17.92$17.81$17.921.35K
Sep 2, 2026$17.845$17.86$17.845$17.861.03K
Sep 1, 2026$17.7371$17.7371$17.7371$17.737178.84
Aug 31, 2026$17.835$17.835$17.835$17.835225.87
Aug 28, 2026$17.845$17.8573$17.795$17.7951.57K
Aug 27, 2026$17.76$17.80$17.76$17.80394.46

Latest EVMT news

The latest Smart Investors Daily articles mentioning EVMT.

Stock researchCompany · Overview

EVMT research

Overview

Company profile and research snapshot.

Company profile

The fund is an actively managed ETF that seeks to invest in a combination of financial instruments that are economically linked to the tradeable metals widely used in the production of an electric vehicle (currently, iron ore, copper, aluminum, nickel and cobalt). Under normal circumstances, the fund invests, either directly or through a wholly-owned subsidiary (the “Subsidiary”), in Commodities Futures, Commodity-Linked Instruments, Commodity-Related Assets and Collateral. The fund is non-diversified.

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Jun 14, 2024

Evome Medical Technologies Announces Securities Issuances

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) announces it has received conditional approval from the TSX Venture Exchange (the “TSXV”) to complete a shares for services transaction with Beacon Securities Limited (“Beacon”) pursuant to ‎which the Company will issue Beacon ‎504,286 ‎common ‎shares of the Company at a deemed price of ‎$0.1983 per share in satisfaction of $100,000 of advisory services. The shares issuable will be subject to a Canadian ‎four-month hold period.‎

GlobeNewswire Inc. · Jun 3, 2024

Evome Medical Technologies Announces Update Call with CEO Mike Seckler for Tuesday, June 4, 2024; Provides Update on Strong Q2

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today provided details on preliminary estimated revenues and margins from April and May 2024, the first two months of the second quarter. Mike Seckler, Chief Executive Officer of the Company, will also hold a call to update shareholders on the first quarter financials, second quarter progress and future plans of the Company.

GlobeNewswire Inc. · Apr 12, 2024

Evome Strengthens Major Creditor Relationship After the Sale of the Simbex Unit to Riddell, LOI Related to Simbex Acquisition Debt is Cancelled

NEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc (the “Company” or “Evome”) highlighted the strengthening credit relationship with Pathward, N.A. (“Pathward”), the Company’s senior lender. As the Company works to sell non-core business units to reduce acquisition debt in an effort to improve operational profitability, Pathward provides working capital to fuel revenue growth of the Company’s new Biodex products. Pathward has featured the strong and growing relationship with Evome as an example of its willingness to fund growth companies:

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By